ArticleTherapeutic advances in hematology2026
More precise risk stratification for de novo acute myeloid leukemia with double-mutation CEBPA.
Article in Therapeutic advances in hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: CEBPA double-mutation (CEBPAdm) defines a favorable-risk subgroup of acute myeloid leukemia (AML), but marked heterogeneity exists, and relapse remains common. More precise prognostic stratification is urgently needed for this population. Objectives: To identify reliable prognostic factors and establish a refined risk stratification model for de novo AML with CEBPAdm. Design: Single-center retrospective observational cohort study. Methods: Samples were collected from AML patients at diagnosis for analysis. The proportions of different surface antigens in the bone marrow were evaluated via flow cytometry. The detection of mutations in AML patients was based on next-generation sequencing (NGS). Multiparametric flow cytometry (MFC) can detect minimal residual disease (MRD). The data were analysed via Statistical Program for Social Sciences Version 27.0 (SPSS 27.0). Results: ①Univariate analysis revealed that high expression of cluster of differentiation antigen 33 (CD33)was unfavourable prognostic factor ( Conclusions: These findings provide a more precise restratification for CEBPAdm patients on the basis of the expression of CD33.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.